Patents by Inventor Christopher McBride
Christopher McBride has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070027150Abstract: 2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.Type: ApplicationFiled: April 14, 2006Publication date: February 1, 2007Inventors: Cornelia Bellamacina, Abran Costales, Brandon Doughan, Susan Fong, Zhenhai Gao, Thomas Hendrickson, Barry Levine, Xiaodong Lin, Timothy Machajewski, Christopher McBride, William Antonios-McCrea, Maureen McKenna, Kris Mendenhall, Alice Rico, Cynthia Shafer, X. Wang, Yi Xia, Yasheen Zhou
-
Patent number: 7071216Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: GrantFiled: March 31, 2003Date of Patent: July 4, 2006Assignee: Chiron CorporationInventors: Paul A. Renhowe, Savithri Ramurthy, Payman Amiri, Barry Haskell Levine, Daniel J. Poon, Sharadha Subramanian, Leonard Sung, Wendy Fantl, Teresa Hansen, Christopher McBride, Cynthia M. Shafer
-
Patent number: 7064215Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.Type: GrantFiled: July 2, 2002Date of Patent: June 20, 2006Assignee: Chiron CorporationInventors: Paul A. Renhowe, Cynthia M. Shafer, Christopher McBride, Joel Benjamin Silver, Sabina Pecchi, Timothy D. Machajewski, William R. McCrea, Jr., Daniel J. Poon, Teresa Thomas
-
Publication number: 20060079564Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.Type: ApplicationFiled: October 27, 2005Publication date: April 13, 2006Inventors: Johanna Jansen, Christopher McBride, Paul Renhowe, Cynthia Shafer
-
Publication number: 20050209456Abstract: A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.Type: ApplicationFiled: March 29, 2005Publication date: September 22, 2005Inventors: Paul Renhowe, Cynthia Shafer, Timothy Machajewski, Sabina Pecchi, Christopher McBride
-
Publication number: 20050203101Abstract: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.Type: ApplicationFiled: May 5, 2004Publication date: September 15, 2005Inventors: Paul Barsanti, Dirksen Bussiere, Stephen Harrison, Carla Heise, Johanna Jansen, Elisa Jazan, Timothy Machajewski, Christopher McBride, William McCrea, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith Pfister, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Joel Silver, Allan Wagman, Marion Wiesmann, Kelly Wayman
-
Publication number: 20050192287Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: October 15, 2004Publication date: September 1, 2005Applicant: Chiron CorporationInventors: Abran Costales, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Joelle Verhagen
-
Publication number: 20050182988Abstract: The preferred embodiments of the present invention are directed to the selective phase lag and time delay of clock signals within a computer system to compensate for additional parasitic capacitance that may be added to that system because of its open architecture. More particularly, the preferred embodiments are directed to clock signal path circuits where each circuit has multiple signal paths of varying lengths. By allowing the clock signals to propagate along a particular path, phase lag or time delay is added to those clock signals. Selection of a particular path for the clock signal is made by activating electrically controlled switches which themselves are activated or deactivated by software programs that run during power-up of the computer system that determine required phase lag or time delay of those clock signals as a function of parasitic capacitance in the computer system.Type: ApplicationFiled: April 15, 2005Publication date: August 18, 2005Applicant: Hewlett-Packard Development Company, L.P.Inventors: Christopher McBride, Paul Brownell, Timothy McJunkin
-
Publication number: 20050054672Abstract: Organic compounds having the formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: July 8, 2004Publication date: March 10, 2005Inventors: Paul Renhowe, Sabina Pecchi, Timothy Machajewski, Cynthia Shafer, Clarke Taylor, William McCrea, Christopher McBride, Elisa Jazan
-
Patent number: 6800760Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: July 3, 2003Date of Patent: October 5, 2004Assignee: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
-
Patent number: 6774237Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: October 30, 2002Date of Patent: August 10, 2004Assignee: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
-
Patent number: 6762194Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: March 12, 2003Date of Patent: July 13, 2004Assignee: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Eliza Jazan
-
Publication number: 20040097545Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein.Type: ApplicationFiled: July 3, 2003Publication date: May 20, 2004Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Christopher McBride, Elisa Jazan
-
Publication number: 20040092535Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.Type: ApplicationFiled: August 19, 2003Publication date: May 13, 2004Applicant: Chiron CorporationInventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Michajewski, Christopher McBride, William R. McCrea, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann
-
Publication number: 20040006101Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein.Type: ApplicationFiled: March 12, 2003Publication date: January 8, 2004Applicant: CHIRON CORPORATIONInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Christopher McBride, Eliza Jazan
-
Publication number: 20030207883Abstract: Organic compounds having the structure I are provided where the variables have the values described herein.Type: ApplicationFiled: July 2, 2002Publication date: November 6, 2003Applicant: Chiron CorporationInventors: Paul A. Renhowe, Cynthia M. Shafer, Christopher McBride, Joel Benjamin Silver, Sabina Pecchi, Timothy D. Machajewski, William R. McCrea, Daniel J. Poon, Teresa Thomas
-
Publication number: 20030158224Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein.Type: ApplicationFiled: October 30, 2002Publication date: August 21, 2003Applicant: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea Jr, Christopher McBride, Elisa Jazan
-
Patent number: 6605617Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: September 11, 2001Date of Patent: August 12, 2003Assignee: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
-
Publication number: 20030028018Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein.Type: ApplicationFiled: April 5, 2002Publication date: February 6, 2003Applicant: Chiron CoporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Christopher McBride, Elisa Jazan
-
Publication number: 20020107392Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein.Type: ApplicationFiled: September 11, 2001Publication date: August 8, 2002Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Christopher McBride, Elisa Jazan